Silicon Maps

10/28/2026

🧬 What if the next frontier in autoimmune disease treatment is learning how to better regulate the immune system?

That’s one of the questions driving cell therapy research—and RESTEM is working to advance the science.

The clinical-stage biotechnology company is developing Restem-L, an investigational cell therapy being studied for idiopathic inflammatory myopathy (IIM), a rare group of diseases that can cause muscle inflammation and weakness.

🔬 A research milestone: In February 2026, RESTEM announced the first patient dosed in its Phase 2/3 IIMPACT study. Researchers are evaluating the therapy’s safety and potential to improve disease activity and reduce reliance on steroids. The results will be important in determining its potential role in treatment.

Why does this matter? Cell therapy research is opening new avenues for investigating how the immune system can be modulated in complex diseases. The challenge now is turning promising research into evidence-backed treatment options.

📍Southern California is home to organizations advancing the future of life sciences. RESTEM Group is among the companies featured on the 2026 Bioscience West Map & Calendar alongside Benitec Biopharma Inc. and Biocom.
https://siliconmaps.com/bioscience-west

The science is evolving. The ecosystem is growing. And the most interesting breakthroughs are worth following.

What breakthrough in cell therapy are you watching most closely?

10/25/2026

🌵 Arizona’s semiconductor story is bigger than chips. It’s an entire ecosystem.

From chipmakers and semiconductor equipment suppliers to advanced electronics manufacturers, Arizona’s technology growth depends on a network of companies working together to turn innovation into reality.

The momentum continues: TSMC announced an additional $100 billion investment in Arizona in July 2026, bringing its planned total investment in the state to $165 billion?

One important part of this ecosystem is Benchmark Electronics, a Tempe-based company providing engineering, technology, and advanced manufacturing services for industries including semiconductor capital equipment and advanced computing.

📍Benchmark is featured at three locations on the Silicon Desert Map, making it a useful reference point for exploring the companies behind Arizona’s technology landscape.
https://siliconmaps.com/silicon-desert

The bigger question: As Arizona’s semiconductor ecosystem expands, which part of the supply chain will become more important next—equipment, advanced packaging, materials, or advanced manufacturing?

10/23/2026

☎️ Behind every great technology ecosystem is a way to keep people connected.

Cloud communications may not grab headlines like AI chips or data centers, but reliable communication is essential to how modern organizations operate.

That’s where 101VOICE comes in.

As businesses and institutions modernize their phone systems, cloud-based communications are helping them rethink how teams connect, collaborate, and stay reachable across locations.

📍 Take a closer look at the Silicon Valley Map. You’ll find 101VOICE alongside technology companies such as Cisco, Intel, Oracle, AMD, and NVIDIA.

Different specialties. Different technologies. One interconnected ecosystem driving innovation across the region.

Because Silicon Valley isn't just about building the next big thing. It's also about keeping the people and organizations behind it connected.

What do you think matters most in business communications today: reliability, flexibility, or seamless integration?

🗺️ Explore the Silicon Valley technology ecosystem:
https://siliconmaps.com/silicon-valley

10/20/2026

What an incredible three days at SEMICON West 2026!🌎

A huge thank-you to everyone who stopped by the Silicon Maps booth in San Francisco!

It was exciting to see so many semiconductor engineers, technical professionals, and industry leaders exploring our regional technology maps, finding companies, and connecting with the broader semiconductor ecosystem.

We were proud to distribute nearly 5,000 complimentary 2027 regional technology map posters throughout the event!

Our maps help bring the semiconductor community together by making it easier to discover companies, explore technology hubs, and see how the industry connects across regions.

Missed us at the show? Explore our maps and discover the companies shaping the industry at www.SiliconMaps.com.

Thank you for making SEMICON West 2026 such a memorable event. We look forward to connecting with you again at SEMICON West in Phoenix next April!

SEMI, SEMI Americas

10/13/2026

Heading to SEMICON West 2026? Come say hello!

Silicon Maps will be there, and we’d love to see you!

If you’re attending, stop by Booth #6803 in the North Hall at Moscone Center. Come meet our team, pick up your complimentary 2027 maps, and connect with us while you’re at the show.

📍 Booth #6803 | North Hall
📅 October 13–15, 2026
📌 Moscone Center, San Francisco, CA

See you in San Francisco

10/10/2026

🧬 The next wave of cancer treatment may be increasingly combination-driven.

AbbVie and Genmab just reported positive Phase 3 results for epcoritamab (EPKINLY) combined with R-CHOP in patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL).

The EPCORE DLBCL-2 study showed a significant improvement in progression-free survival compared with R-CHOP alone — adding to the momentum around bispecific antibodies and combination approaches in blood cancer.

And AbbVie’s pipeline is expanding beyond oncology.

In September, AbbVie completed its $10.9 billion acquisition of Apogee Therapeutics, adding late-stage immunology programs targeting conditions including atopic dermatitis and asthma.

From Cambridge and Boston to the broader East Coast life sciences corridor, AbbVie is part of an ecosystem where biotech, pharma, research institutions and emerging technologies continue to converge.

📍 Explore the East Coast life science ecosystem: https://siliconmaps.com/bioscience-east

What comes next for bispecific antibodies — and how far can combination therapies push the standard of care?

10/07/2026

🧬 The peptide manufacturing boom is reshaping the biopharma supply chain.

As demand for peptide-based therapies continues to grow, manufacturers are investing heavily in the capacity and technology needed to move these therapies from development to commercial scale.

Bachem is a good example of this shift.

In July, Bachem announced plans to invest more than CHF 500 million in a new large-scale production facility in Sisslerfeld, Switzerland, with commercial production expected to begin in 2030. The company also reported CHF 326.4 million in first-half 2026 sales and expects 35–40% sales growth in local currencies for the full year.

The expansion comes as peptide manufacturing faces growing demand, particularly from next-generation therapeutics. Bachem has also been investing in new approaches to peptide and oligonucleotide manufacturing, including more sustainable production methods.

And the Southern California connection is significant: Bachem's Vista facility specializes in medium-to-large-scale peptide API manufacturing, with more than 225 employees and hundreds of kilograms of annual capacity.

📍 On the Bioscience West Map, Bachem sits within a remarkably dense life-sciences ecosystem alongside companies such as Pfizer, Takeda, Novartis, AbbVie and FUJIFILM Biotechnologies.
https://siliconmaps.com/bioscience-west-map

As peptide therapeutics scale, will manufacturing capacity become one of the biggest bottlenecks in biopharma?

10/06/2026

10/06/2026

10/02/2026

🧠 Micron Technology is showing just how critical memory has become to the AI era — and its latest results reflect that shift.

Micron reported record fiscal 2026 results on September 30, with $54.23 billion in fourth-quarter revenue and $133.19 billion for the full year. The company said AI-driven demand and strong ex*****on are positioning it for an even stronger fiscal 2027.

But the story goes beyond financial results.

In September, Micron demonstrated the world’s first 512GB DDR5 memory module for next-generation servers, capable of speeds up to 9,200 MT/s. The company says the technology is designed to support increasingly demanding AI, analytics and data-center workloads, while reducing operating power by more than 60% compared with four 128GB modules. AMD and Intel are among the companies validating the technology.

Micron is also expanding its AI ecosystem. Its strategic agreement with Anthropic spans memory and storage architecture, supply, enterprise AI adoption and a strategic investment — connecting memory innovation directly to the infrastructure needed for next-generation AI.

📍 Zoom in on Micron on the Silicon World Map and you'll see something bigger: a global network of companies spanning semiconductors, memory, computing, equipment, AI and advanced manufacturing.

From Intel, AMD and NXP Semiconductors to Samsung Semiconductor, SK hynix, Lam Research, Applied Materials, Tokyo Electron US and many others, the map offers a snapshot of how interconnected the global technology ecosystem has become.

The interesting question: As AI workloads continue to scale, how much more important will memory become to the future of computing?

🗺️ Explore the Silicon World technology ecosystem:

https://siliconmaps.com/silicon-world-map/